ML-179

Confirm delete?

ML-179

Zoom

Cat No: 15180

Biochemicals - Receptor Pharmacology

ML-179 is a potent inverse agonist of liver receptor homolog-1 (LRH-1) (IC50 = 320 nM) with maximum efficacy of 40% repression.{24526} It is inactive at the related steroidogenic factor-1 transcriptional activator.{24526} Through LRH-1, ML-180 alters ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

3-cyclohexyl-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-2,4(1H,3H)-pyrimidinedione

Correlated keywords:

nuclears receptors signal transduction intracellular signaling cancers genes regulations MLs 179 ML179 inverse agonist LRH-1 LRH1 LRHs 1 one potent liver homolog-1 homologs one steroidogenic factors factor-1 SF1 SF-1 SFs haptoglobin serums amyloids proteins A1 A4 A-1 A-4 As 4 four estrogen-receptors estrogens negative MDA-MB-231 MDAMB231 MDA MB 231 breasts cells StAR acute regulatory promoters CIDs 45100448 CID45100448 CID-45100448

Product Overview:
ML-179 is a potent inverse agonist of liver receptor homolog-1 (LRH-1) (IC50 = 320 nM) with maximum efficacy of 40% repression.{24526} It is inactive at the related steroidogenic factor-1 transcriptional activator.{24526} Through LRH-1, ML-180 alters the expression of haptoglobin and serum amyloid proteins A1 and A4, induces the death of estrogen-receptor negative MDA-MB-231 breast cancer cells, and inhibits the steroidogenic acute regulatory promoter (IC50 = 2.12 µM).{24526}

Size	1 mg
Shipping	dry ice
CAS Number	1883548-87-5
Molecular Formula	C₂₁H₂₅F₃N₄O₂
SMILES	O=C(N1)N(C2CCCCC2)C(C=C1N(CC3)CCN3C4=CC=CC(C(F)(F)F)=C4)=O
Molecular Weight	422,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2933.59
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.